Plasma resistin levels and risk of myocardial infarction and ischemic stroke

Journal of Clinical Endocrinology and Metabolism

Volumn 93, Issue 7, 2008, Pages 2647-2653

  Weikert, Cornelia ^a   Westphal, Sabine ^b   Berger, Klaus ^c   Dierkes, Jutta ^b   Möhlig, Matthias ^a,d   Spranger, Joachim ^a,d   Rimm, Eric B ^e,f   Willich, Stefan N ^d   Boeing, Heiner ^a   Pischon, Tobias ^a,d  

^a GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

^c UNIVERSITY OF MÜNSTER   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; RESISTIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEART INFARCTION; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY;

EID: 47549107695     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2007-2735     Document Type: Article

References (40)

1. Steppan CM, Lazar MA 2004 The current biology of resistin. J Intern Med 255:439-447
2. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA 2001 The hormone resistin links obesity to diabetes. Nature 409:307-312
3. Savage DB, Sewter CP, Klenk ES, Segal DG, Vidal-Puig A, Considine RV, O'Rahilly S 2001 Resistin / Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-γ action in humans. Diabetes 50:2199-2202
4. Nagaev I, Smith U 2001 Insulin resistance and type 2 diabetes are not related to resistin expression in human fat cells or skeletal muscle. Biochem Biophys Res Commun 285:561-564
5. Patel L, Buckels AC, Kinghorn IJ, Murdock PR, Holbrook JD, Plumpton C, Macphee CH, Smith SA 2003 Resistin is expressed in human macrophages and directly regulated by PPARγ activators. Biochem Biophys Res Commun 300:472-476
6. Verma S, Li SH, Wang CH, Fedak PW, Li RK, Weisel RD, Mickle DA 2003 Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation 108:736-740
7. Calabro P, Samudio I, Willerson JT, Yeh ET 2004 Resistin promotes smooth muscle cell proliferation through activation of extracellular signal-regulated kinase 1/2 and phosphatidylinositol 3-kinase pathways. Circulation 110:3335-3340
8. Bo S, Gambino R, Pagani A, Guidi S, Gentile L, Cassader M, Pagano GF 2005 Relationships between human serum resistin, inflammatory markers and insulin resistance. Int J Obes (Lond) 29:1315-1320
9. Kunnari A, Ukkola O, Paivansalo M, Kesaniemi YA 2006 High plasma resistin level is associated with enhanced highly sensitive C-reactive protein and leukocytes. J Clin Endocrinol Metab 91:2755-2760
10. Shetty GK, Economides PA, Horton ES, Mantzoros CS, Veves A 2004 Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care 27:2450-2457
11. Burnett MS, Lee CW, Kinnaird TD, Stabile E, Durrani S, Dullum MK, Devaney JM, Fishman C, Stamou S, Canos D, Zbinden S, Clavijo LC, Jang GJ, Andrews JA, Zhu J, Epstein SE 2005 The potential role of resistin in atherogenesis. Atherosclerosis 182:241-248
12. Ohmori R, Momiyama Y, Kato R, Taniguchi H, Ogura M, Ayaori M, Nakamura H, Ohsuzu F 2005 Associations between serum resistin levels and insulin resistance, inflammation, and coronary artery disease. J Am Coll Cardiol 46:379-380
13. Pischon T, Bamberger CM, Kratzsch J, Zyriax BC, Algenstaedt P, Boeing H, Windler E 2005 Association of plasma resistin levels with coronary heart disease in women. Obes Res 13:1764-1771
14. Boeing H, Korfmann A, Bergmann MM 1999 Recruitment procedures of EPIC-Germany. European Investigation into Cancer and Nutrition. Ann Nutr Metab 43:205-215
15. Bergmann MM, Bussas U, Boeing H 1999 Follow-up procedures in EPIC-Germany - data quality aspects. European Prospective Investigation into Cancer and Nutrition. Ann Nutr Metab 43:225-234
16. Prentice R 1986 A case-cohort design for epidemiologic cohort studies and disease prevention trials. Biometrika 73:1-11
17. Miettinen O 1982 Design options in epidemiologic research. An update. Scand J Work Environ Health 8(Suppl 1):7-14
18. Salomaa V, Matei C, Aleksic N, Sansores-Garcia L, Folsom AR, Juneja H, Chambless LE, Wu KK 1999 Soluble thrombomodulin as a predictor of incident coronary heart disease and symptomless carotid artery atherosclerosis in the Atherosclerosis Risk in Communities (ARIC) Study: a case-cohort study. Lancet 353:1729-1734
19. Weikert C, Berger K, Heidemann C, Bergmann MM, Hoffmann K, Klipstein-Grobusch K, Boeing H 2007 Joint effects of risk factors for stroke and transient ischemic attack in a German population: The EPIC Potsdam Study. J Neurol 254:315-321
20. World Health Organisation 1992 International statistical classification of diseases and related health problems. Geneva: World Health Organisation
21. Kroke A, Bergmann MM, Lotze G, Jeckel A, Klipstein-Grobusch K, Boeing H 1999 Measures of quality control in the German component of the EPIC study. European Prospective Investigation into Cancer and Nutrition. Ann Nutr Metab 43:216-224
22. Bohlscheid-Thomas S, Hoting I, Boeing H, Wahrendorf J 1997 Reproducibility and relative validity of energy and macronutrient intake of a food frequency questionnaire developed for the German part of the EPIC project. European Prospective Investigation into Cancer and Nutrition. Int J Epidemiol 26(Suppl 1):S71-S81
23. Lunn M, McNeil D 1995 Applying Cox regression to competing risks. Biometrics 51:524-532
24. Glynn RJ, Rosner B 2005 Comparison of risk factors for the competing risks of coronary heart disease, stroke, and venous thromboembolism. Am J Epidemiol 162:975-982
25. Burnett MS, Devaney JM, Adenika RJ, Lindsay R, Howard BV 2006 Cross-sectional associations of resistin, coronary heart disease, and insulin resistance. J Clin Endocrinol Metab 91:64-68
26. Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ 2005 Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 111:932-939
27. Pischon T, Mohlig M, Hoffmann K, Spranger J, Weikert C, Willich SN, Pfeiffer AF, Boeing H 2007 Comparison of relative and attributable risk of myocardial infarction and stroke according to C-reactive protein and low-density lipoprotein cholesterol levels. Eur J Epidemiol 22:429-438
28. Jung HS, Park KH, Cho YM, Chung SS, Cho HJ, Cho SY, Kim SJ, Kim SY, Lee HK, Park KS 2006 Resistin is secreted from macrophages in atheromas and promotes atherosclerosis. Cardiovasc Res 69:76-85
29. Ross R 1999 Atherosclerosis - an inflammatory disease. N Engl J Med 340:115-126
30. Lehrke M, Reilly MP, Millington SC, Iqbal N, Rader DJ, Lazar MA 2004 An inflammatory cascade leading to hyperresistinemia in humans. PLoS Med 1:e45
31. Vendrell J, Broch M, Vilarrasa N, Molina A, Gomez JM, Gutierrez C, Simon I, Soler J, Richart C 2004 Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity. Obes Res 12:962-971
32. Yusuf HR, Giles WH, Croft JB, Anda RF, Casper ML 1998 Impact of multiple risk factor profiles on determining cardiovascular disease risk. Prev Med 27:1-9
33. Patel A, Woodward M, Campbell DJ, Sullivan DR, Colman S, Chalmers J, Neal B, MacMahon S 2005 Plasma lipids predict myocardial infarction, but not stroke, in patients with established cerebrovascular disease. Eur Heart J 26:1910-1915
34. Dullaart RP, de Vries R, van Tol A, Sluiter WJ 2007 Lower plasma adiponectin is a marker of increased intima-media thickness associated with type 2 diabetes mellitus and with male gender. Eur J Endocrinol 156:387-394
35. Norata GD, Ongari M, Garlaschelli K, Raselli S, Grigore L, Catapano AL 2007 Plasma resistin levels correlate with determinants of the metabolic syndrome. Eur J Endocrinol 156:279-284
36. Seese B, Brandt-Pohlmann M, Moshage W, Achenbach S, Schwarz T, Bachmann K 1998 Evaluation of the association between coronary calcification detected by electron beam computed tomography and atherosclerosis of extracranial carotid arteries in vivo. Int J Angiol 7:301-306
37. Weikert C, Westphal S, Luley C, Willich SN, Boeing H, Pischon T 2007 Within-subject variation of plasma resistin levels over a 1-year period. Clin Chem Lab Med 45:899-902
38. Gruendel S, Weickert MO, Garcia AL, Wagner K, Pfeiffer AF, Harsch I, Koebnick C 2006 Serum resistin increases in a postprandial state during liquid meal challenge test in healthy human subjects. J Endocrinol Invest 29:RC27-RC30
39. Lee JH, Chan JL, Yiannakouris N, Kontogianni M, Estrada E, Seip R, Orlova C, Mantzoros CS 2003 Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab 88:4848-4856
40. Gerber M, Boettner A, Seidel B, Lammert A, Bar J, Schuster E, Thiery J, Kiess W, Kratzsch J 2005 Serum resistin levels of obese and lean children and adolescents: biochemical analysis and clinical relevance. J Clin Endocrinol Metab 90:4503-4509